In Re Philip Morris Int'l Inc. SEC. Litig., 89 F.4th 408

PMI is a major tobacco company that developed "IQOS," a smoke-free tobacco product, and sought to market it as a safer alternative to traditional cigarettes.
Investors (Union Asset Mgmt. & Teamsters Local 710 Pension Fund) filed a securities-fraud class action against PMI and its executives, alleging false and misleading statements about IQOS’s scientific studies and its projected sales, violating Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5.
PMI’s statements included descriptions of its scientific studies’ rigor and compliance with Good Clinical Practice (GCP), as well as projections about IQOS sales in Japan.
During the class period, PMI faced setbacks such as negative reports about its studies and a partial rejection from an FDA advisory panel, adversely affecting its stock price.
The FDA ultimately approved IQOS for U.S. sale and allowed "reduced exposure" marketing claims, effectively endorsing PMI’s key scientific assertions.
The district court dismissed the Investors’ claims, finding no adequately pleaded falsity or scienter; the Investors appealed.

Issue	Plaintiff's Argument	Defendant's Argument	Held
Are PMI’s statements about compliance with broad, subjective scientific standards (like GCP) fact or opinion?	Statements about GCP compliance were factual and thus actionable.	Such statements are inherently subjective opinions, not objective facts.	Such statements are opinions, not facts, and thus inactionable.
Are PMI’s interpretations of scientific data, later endorsed by FDA, per se reasonable?	PMI’s data interpretations were unreasonable/misleading, regardless of later FDA endorsement.	FDA’s later endorsement proves PMI’s interpretations were reasonable as a matter of law.	FDA endorsement makes the statements per se reasonable and not actionable.
Were PMI’s projections about IQOS sales in Japan misleading or omitted required disclosures?	PMI misled investors and failed to disclose known unfavorable trends, violating disclosure rules.	PMI’s projections were either accurate or forward-looking (protected by PSLRA); required trends were disclosed.	Statements were accurate or protected forward-looking statements; required trends were adequately disclosed.
Can the executive defendants be liable under control-person theory?	They are liable as they controlled PMI during alleged primary violations.	No primary violation, so no control-person liability.	No Section 10(b) violation, so Section 20(a) claim fails.

Omnicare, Inc. v. Laborers Dist. Council Const. Indus. Pension Fund, 575 U.S. 175 (explains distinction between fact and opinion statements in securities law)
Tongue v. Sanofi, 816 F.3d 199 (interpretation of scientific data reasonable if ultimately accepted by the FDA)
Fait v. Regions Fin. Corp., 655 F.3d 105 (opinion vs. factual statement distinction in securities filings)
Basic Inc. v. Levinson, 485 U.S. 224 (materiality in securities fraud)
Stoneridge Inv. Partners, LLC v. Sci.-Atlanta, Inc., 552 U.S. 148 (elements of securities fraud claim)
Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308 (scienter standard for securities fraud)
ECA & Loc. 134 IBEW Joint Pension Tr. of Chi. v. JP Morgan Chase Co., 553 F.3d 187 (pleading standards in securities fraud)